157356-74-6

Basic information

• Product Name: OlMesartan MedoxoMil iMpurity V
• Synonyms: OlMesartan MedoxoMil iMpurity V;ethyl 4-(prop-1-en-2-yl)-2-propyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate
• CAS NO: 157356-74-6
• Molecular Formula: C45H42N6O2
• Molecular Weight: 698.85
• Mol File: 157356-74-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 864.8±75.0 °C(Predicted)
• Appearance: /
• Density: 1.16±0.1 g/cm3(Predicted)
• PKA: 4.15±0.60(Predicted)
• CAS DataBase Reference: OlMesartan MedoxoMil iMpurity V(CAS DataBase Reference)
• NIST Chemistry Reference: OlMesartan MedoxoMil iMpurity V(157356-74-6)
• EPA Substance Registry System: OlMesartan MedoxoMil iMpurity V(157356-74-6)

Safety Data

• Hazardous Substances Data: 157356-74-6(Hazardous Substances Data)

Upstream product

• 124750-51-2 N-(triephenylmethyl)-5-<4'-(bromomethyl)-biphenyl-2-yl>tetrazole 
• 144690-33-5 ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({2'-[1-(triphenylmethyl)-1H-1,2,3,4-tetrazol-5-yl]-[1,1'-biphenyl]-4-yl}methyl)-1H-imidazole-5-carboxylate 
• 144689-93-0 ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate 

Relevant articles and documents

Improved synthesis process of olmesartan medoxomil derivatives

The present invention relates to an improved olmesartan medoxomil derivative preparation method. More specifically, the olmesartan medoxomil derivative preparation method includes the steps of: initiating a coupling reaction between imidazole compounds and biphenyl methyl halide compounds; initiating a de-esterification reaction of the products of the coupling reaction; and initiating a condensation reaction between the de-esterified products with dioxolen derivatives. The present invention can optimize the reaction conditions of the coupling and de-esterification reactions to minimixe the content of the conventionally produced byproducts and residual solvent to significantly increase the yield and purity of the target products. The final olmesartan medoxomil derivatives obtained by using the method has the residual solvent content less than or equal to 500 ppm, thereby being lowered to 1/10 or less of the ICH guidelines.